What is the current valuation of the Glomerulonephritis Market in 2025?

The Glomerulonephritis Market is valued at approximately 11.67 USD Billion in 2024. Read More

What is the projected market size for the Glomerulonephritis Market by 2035?

The market is expected to reach a valuation of 18.04 USD Billion by 2035. Read More

What is the expected CAGR for the Glomerulonephritis Market during the forecast period 2025 - 2035?

The market is projected to grow at a CAGR of 4.04% from 2025 to 2035. Read More

Which segment of the Glomerulonephritis Market had the highest valuation in 2024?

Lupus Nephritis was the leading segment with a valuation of 4.67 USD Billion in 2024. Read More

What are the key types of glomerulonephritis and their projected market values?

Membranous Nephropathy and Minimal Change Disease are projected to grow to 3.8 USD Billion and 3.0 USD Billion, respectively, by 2035. Read More

Which diagnostic method is expected to dominate the Glomerulonephritis Market?

Kidney Function Tests are anticipated to lead with a projected value of 7.54 USD Billion by 2035. Read More

What treatment options are available in the Glomerulonephritis Market?

Immunosuppressive Therapy is expected to reach 4.5 USD Billion by 2035, making it a key treatment option. Read More

Who are the major players in the Glomerulonephritis Market?

Key players include Bristol-Myers Squibb, Roche, Novartis, and Pfizer, among others. Read More

What is the expected growth in the end-user segment of the Glomerulonephritis Market?

Hospitals are projected to grow to 7.04 USD Billion by 2035, indicating a strong demand in this segment. Read More

How does the Glomerulonephritis Market compare across different treatment options?

Corticosteroids and Dialysis are also significant, with projected values of 3.5 USD Billion and 5.04 USD Billion, respectively, by 2035. Read More

Glomerulonephritis Market

ID: MRFR/HC/35406-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Glomerulonephritis Market Research Report By Type (Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis, IgA Nephropathy, Lupus Nephritis), By Diagnosis (Urinalysis, Blood Tests, Kidney Biopsy, Imaging Tests, Kidney Function Tests), By Treatment (Immunosuppressive Therapy, Corticosteroids, Plasmapheresis, Renin-Angiotensin System Inhibitors, Dialysis), By End User (Hospitals, Specialty Clinics, Home Care Settings, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 Membranous Nephropathy
4.1.2 Minimal Change Disease
4.1.3 Focal Segmental Glomerulosclerosis
4.1.4 IgA Nephropathy
4.1.5 Lupus Nephritis
4.2 Healthcare, BY Diagnosis (USD Billion)
4.2.1 Urinalysis
4.2.2 Blood Tests
4.2.3 Kidney Biopsy
4.2.4 Imaging Tests
4.2.5 Kidney Function Tests
4.3 Healthcare, BY Treatment (USD Billion)
4.3.1 Immunosuppressive Therapy
4.3.2 Corticosteroids
4.3.3 Plasmapheresis
4.3.4 Renin-Angiotensin System Inhibitors
4.3.5 Dialysis
4.4 Healthcare, BY End User (USD Billion)
4.4.1 Hospitals
4.4.2 Specialty Clinics
4.4.3 Home Care Settings
4.4.4 Research Institutes
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Bristol-Myers Squibb (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Roche (CH)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Novartis (CH)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Pfizer (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Merck & Co. (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Amgen (US)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Gilead Sciences (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Sanofi (FR)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 AstraZeneca (GB)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY DIAGNOSIS
6.5 US MARKET ANALYSIS BY TREATMENT
6.6 US MARKET ANALYSIS BY END USER
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS
6.9 CANADA MARKET ANALYSIS BY TREATMENT
6.10 CANADA MARKET ANALYSIS BY END USER
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS
6.14 GERMANY MARKET ANALYSIS BY TREATMENT
6.15 GERMANY MARKET ANALYSIS BY END USER
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY DIAGNOSIS
6.18 UK MARKET ANALYSIS BY TREATMENT
6.19 UK MARKET ANALYSIS BY END USER
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS
6.22 FRANCE MARKET ANALYSIS BY TREATMENT
6.23 FRANCE MARKET ANALYSIS BY END USER
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
6.26 RUSSIA MARKET ANALYSIS BY TREATMENT
6.27 RUSSIA MARKET ANALYSIS BY END USER
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS
6.30 ITALY MARKET ANALYSIS BY TREATMENT
6.31 ITALY MARKET ANALYSIS BY END USER
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS
6.34 SPAIN MARKET ANALYSIS BY TREATMENT
6.35 SPAIN MARKET ANALYSIS BY END USER
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS
6.43 CHINA MARKET ANALYSIS BY TREATMENT
6.44 CHINA MARKET ANALYSIS BY END USER
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS
6.47 INDIA MARKET ANALYSIS BY TREATMENT
6.48 INDIA MARKET ANALYSIS BY END USER
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS
6.51 JAPAN MARKET ANALYSIS BY TREATMENT
6.52 JAPAN MARKET ANALYSIS BY END USER
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT
6.60 MALAYSIA MARKET ANALYSIS BY END USER
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS
6.63 THAILAND MARKET ANALYSIS BY TREATMENT
6.64 THAILAND MARKET ANALYSIS BY END USER
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
6.67 INDONESIA MARKET ANALYSIS BY TREATMENT
6.68 INDONESIA MARKET ANALYSIS BY END USER
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT
6.72 REST OF APAC MARKET ANALYSIS BY END USER
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
6.76 BRAZIL MARKET ANALYSIS BY TREATMENT
6.77 BRAZIL MARKET ANALYSIS BY END USER
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS
6.80 MEXICO MARKET ANALYSIS BY TREATMENT
6.81 MEXICO MARKET ANALYSIS BY END USER
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT
6.85 ARGENTINA MARKET ANALYSIS BY END USER
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT
6.102 REST OF MEA MARKET ANALYSIS BY END USER
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
6.112 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
6.114 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.2.3 BY TREATMENT, 2025-2035 (USD Billion)
7.2.4 BY END USER, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.3.3 BY TREATMENT, 2025-2035 (USD Billion)
7.3.4 BY END USER, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.4.3 BY TREATMENT, 2025-2035 (USD Billion)
7.4.4 BY END USER, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.5.3 BY TREATMENT, 2025-2035 (USD Billion)
7.5.4 BY END USER, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.6.3 BY TREATMENT, 2025-2035 (USD Billion)
7.6.4 BY END USER, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.7.3 BY TREATMENT, 2025-2035 (USD Billion)
7.7.4 BY END USER, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.8.3 BY TREATMENT, 2025-2035 (USD Billion)
7.8.4 BY END USER, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.9.3 BY TREATMENT, 2025-2035 (USD Billion)
7.9.4 BY END USER, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.10.3 BY TREATMENT, 2025-2035 (USD Billion)
7.10.4 BY END USER, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.11.3 BY TREATMENT, 2025-2035 (USD Billion)
7.11.4 BY END USER, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.12.3 BY TREATMENT, 2025-2035 (USD Billion)
7.12.4 BY END USER, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.13.3 BY TREATMENT, 2025-2035 (USD Billion)
7.13.4 BY END USER, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.14.3 BY TREATMENT, 2025-2035 (USD Billion)
7.14.4 BY END USER, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.15.3 BY TREATMENT, 2025-2035 (USD Billion)
7.15.4 BY END USER, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.16.3 BY TREATMENT, 2025-2035 (USD Billion)
7.16.4 BY END USER, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.17.3 BY TREATMENT, 2025-2035 (USD Billion)
7.17.4 BY END USER, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.18.3 BY TREATMENT, 2025-2035 (USD Billion)
7.18.4 BY END USER, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.19.3 BY TREATMENT, 2025-2035 (USD Billion)
7.19.4 BY END USER, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.20.3 BY TREATMENT, 2025-2035 (USD Billion)
7.20.4 BY END USER, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.21.3 BY TREATMENT, 2025-2035 (USD Billion)
7.21.4 BY END USER, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.22.3 BY TREATMENT, 2025-2035 (USD Billion)
7.22.4 BY END USER, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.23.3 BY TREATMENT, 2025-2035 (USD Billion)
7.23.4 BY END USER, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.24.3 BY TREATMENT, 2025-2035 (USD Billion)
7.24.4 BY END USER, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.25.3 BY TREATMENT, 2025-2035 (USD Billion)
7.25.4 BY END USER, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.26.3 BY TREATMENT, 2025-2035 (USD Billion)
7.26.4 BY END USER, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.27.3 BY TREATMENT, 2025-2035 (USD Billion)
7.27.4 BY END USER, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.28.3 BY TREATMENT, 2025-2035 (USD Billion)
7.28.4 BY END USER, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.29.3 BY TREATMENT, 2025-2035 (USD Billion)
7.29.4 BY END USER, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
7.30.3 BY TREATMENT, 2025-2035 (USD Billion)
7.30.4 BY END USER, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Membranous Nephropathy
Minimal Change Disease
Focal Segmental Glomerulosclerosis
IgA Nephropathy
Lupus Nephritis

Healthcare By Diagnosis (USD Billion, 2025-2035)

Urinalysis
Blood Tests
Kidney Biopsy
Imaging Tests
Kidney Function Tests

Healthcare By Treatment (USD Billion, 2025-2035)

Immunosuppressive Therapy
Corticosteroids
Plasmapheresis
Renin-Angiotensin System Inhibitors
Dialysis

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Specialty Clinics
Home Care Settings
Research Institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓